search query: @indexterm PHARMACEUTICAL INDUSTRY / total: 673
references: 78-87 / 673
« previous page | next page »
 titleyearauthor
78.
Why lower drug prices benefit institutional investors: An application of universal ownership theory
Corporate governance
2007 : MAY, VOL. 15:3, p. 455-466
 2007 Lippman, S.
Rosan, D.E.
Seitchik, A.
79.
The front end of innovation in an era of industry convergence: evidence from nutraceuticals and functional foods
R & D Management
2006 : NOV, VOL. 36:5, p. 487-498
 2006 Bröring, S.
Cloutier, L.M.
Leker, J.
80.
Nordic compensation schemes for drug injuries
Journal of Consumer Policy
2006 : JUN, VOL. 29:2, p. 143-175
 2006 Hodges, C.
81.
Inter-firm R&D networks: the importance of strategic network capabilities for high-tech partnership formation
British Journal of Management
2006 : MAR, VOL 17:1, p. 39-53
 2006 Hagedoorn, J.
Roijakkers, N.
Kranenburg, H. van
82.
Trust, Burroughs Wellcome & Co. and the foundation of a modern pharmaceutical industry in Britain, 1880-1914
Business history
2006 : JUL, VOL. 48:3, p. 376-398
 2006 Church, R.
83.
The outsourcing of R&D through acquisitions in the pharmaceutical industry
Journal of Financial Economics
2006 : MAY, VOL. 80:2, p. 351-383
 2006 Higgins, M.J.
Rodriguez, D.
84.
Consumer believability of information in direct-to-consumer (DTC) advertising of prescription drugs
Journal of Business Ethics
2006 : FEB II, VOL 63:4, p. 333-343
 2006 Beltramini, R. F.
85.
The role of CRM in e-business: an application model for the pharmaceutical industry
Journal of international marketing and marketing research
2006 : FEB, VOL. 31:1, p. 31-43
 2006 Sanayei, A.
Shad, A. A.
86.
Patent rights or patent wrongs? The case of patent rights on AIDS drugs
Business Ethics
2006 : JUL, VOL 15:3, p. 299-305
 2006 Byrne, S. (et al.)
87.
Is there a morally right price for anti-retroviral drugs in the developing world?
Business Ethics
2006 : JAN, VOL 15:1, p. 29-43
 2006 Brennan, R.
Baines, P.
« previous page | next page »
SCIMA